All lobbying filings

INNOVATIVE FEDERAL STRATEGIES, LLC

Lobbying for ACURX PHARMACEUTICALS, INC. · biopharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · New York · House · Senate · $30,000.00 income · posted Jul 18, 2025

Official filing document

Bills named in this filing 2

HR 4026
POST Act of 2025
S 2296
National Defense Authorization Act for Fiscal Year 2026

Lobbying activity 2

Budget/Appropriations

H.R.4026/S.____, Department of Defense Appropriations Bill, 2026, Title IV, all provisions related to biodefense preparedness. H.R.____/S.____, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, Title II, all provisions related research and clinical trials for the development of antibiotics for infections caused by bacteria listed as priority pathogens.

Defense

H.R.____/S.2296, National Defense Authorization Act, 2026, Title II, all provisions related to biodefense preparedness.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.